Jounce Therapeutics Added to NASDAQ Biotechnology Index
Jounce Therapeutics Added to NASDAQ Biotechnology Index Jounce Therapeutics Added to NASDAQ Biotechnology Index CAMBRIDGE, Mass., Dec. 16, 2020 — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock ...
Source: globalbankingandfinance.com